Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616651 · ClinicalTrials.gov registry record · NA
Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04616651: Clinical Trial NA study, sponsored by University of Michigan Rogel Cancer Center.
NCT04616651 is a NA study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04616651, a NA study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to study the feasibility and acceptability of the Open to Options (O2O) Chatbot prototype. The O2O program is an existing patient support program with content currently delivered via in-person counseling with a trained mental health professional or via an existing web-based program (Let's Talk Treatment Options).The Chatbot is an automated, menu-based agent being developed in this study to extend the reach and accessibility of the O2O program via the Chatbot's "virtual coaching".
Primary Outcome
The feasibility of integrating an Open to Options (O2O) Chatbot into the clinical workflow, assessed by the number of patients who accept the invitation to receive more information about the study, among all those invited.
Interventions
- BEHAVIORAL Online Survey
- BEHAVIORAL Chatbot prototype
- BEHAVIORAL Open to Options (O2O) Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-25 |
| Est. Completion | 2021-08-10 |
| Phase | NA |
Why NCT04616651 stopped before completion
NCT04616651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Online Survey is the first listed.
NCT04616651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04616651 about?
NCT04616651 is a clinical study titled "Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program". This study is designed to study the feasibility and acceptability of the Open to Options (O2O) Chatbot prototype. The O2O program is an existing patient support program with content currently delivered via in-person counseling with a trained mental health professional or via an existing web-based pr...
What is the current status of trial NCT04616651?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2021-03-25. Estimated completion is 2021-08-10.
What interventions are being tested in trial NCT04616651?
The interventions under investigation include: Online Survey (BEHAVIORAL), Chatbot prototype (BEHAVIORAL), Open to Options (O2O) Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04616651?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04616651's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI